AIR 001 - AiRNA Pharmaceuticals
Alternative Names: AIR-001 - AiRNA PharmaceuticalsLatest Information Update: 14 Apr 2025
At a glance
- Originator AiRNA Pharmaceuticals
- Class Oligonucleotides
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alpha 1-antitrypsin deficiency
Most Recent Events
- 14 Apr 2025 AIR 001 - AiRNA Pharmaceuticals is available for licensing as of 14 Apr 2025. https://airna.com/science-platform/ (AiRNA Pharmaceuticals website, April 2025)
- 01 Apr 2025 Preclinical trials in Alpha 1-antitrypsin deficiency in USA (Parenteral), before April 2025
- 01 Apr 2025 AiRNA Pharmaceuticals plans to file clinical trial application for AIR 001 for alpha-1 antitrypsin deficiency in 2H 2025